Nav: Home

UNC to break new ground in health innovation by sharing work with no strings attached

September 16, 2015

The University of North Carolina at Chapel Hill is the newest member of a pioneering international partnership that aims to completely map the single most successful targets for cancer drugs known to date and will share their work with no fees or restrictions on intellectual property. The unrestricted use of this map could lead to breakthrough medicines not only in the realm of cancer, but also for rheumatoid arthritis and a host of neurodegenerative disorders, including Parkinson's and Alzheimer's.

The partnership is known as the Structural Genomics Consortium, which began 11 years ago and includes Oxford University, the University of Toronto and the State University of Campinas in São Paulo, Brazil. UNC-Chapel Hill is the consortium's newest member and has launched the SGC-UNC on campus, thanks to startup funding from the UNC Eshelman Institute for Innovation, which was created by Fred Eshelman's gift to the pharmacy school in 2014.

"Because of Fred Eshelman's historic $100 million gift, we have been able to create the first SGC hub in the U.S.," said Chancellor Carol L. Folt. "SGC-UNC is going to help identify the best new targets for discovering breakthrough medicines, and we have Dr. Eshelman and an incredibly talented group of faculty, staff and students to thank for this remarkable effort."

UNC-Chapel Hill will focus on developing chemical tools that allow researchers to home in on the function of a family of proteins called kinases, enzymes that set in motion the machinery for cell growth and survival. They will then use these tools to create a functional map of this family, such that similar kinases would be grouped together. The map will help pharmaceutical companies, industry and academia narrow down on kinases they want to target for drug development depending on the disease they want to treat. Without the map, it is unclear which kinases are potential drug targets for any one disease.

"It's like exploring and opening up the American West," said Tim Willson, chief scientist of the Structural Genomics Consortium at UNC-Chapel Hill. "Everyone suspected there was something interesting out there, but until somebody went out there and made a map, people just didn't know where to build the railroads, or a new settlement. The pioneers had to go explore for the good of everyone and bring that knowledge back to share with everyone."

Although kinases have been one of the most productive areas of drug development, they are largely unexplored. Out of a family of approximately 500 proteins, only about 50 have been studied in depth, which has led to the creation of 26 drugs, 25 of which work to fight cancer - an overwhelming success rate for drug discovery. But despite their high-stakes therapeutic potential, more than 80 percent of kinases remain untapped due to the cost, risk and complexity of creating the chemical tools that yield such a map.

UNC has already seen success leveraging the SGC's work with protein kinases. In 2009, researchers at the UNC Lineberger Comprehensive Cancer Center identified a kinase that plays a role in various forms of cancer. At that time, the SGC, which did not include UNC-Chapel Hill, had already made the 3D structure of the kinase available to the public. Scientists then used the structure of the kinase to rapidly design and synthesize new compounds that shut down activity in human cancer cells.

Their work resulted in a spinoff company, Meryx, which was created in 2013 to develop new therapeutics based on the kinase inhibitors created at UNC-Chapel Hill.

"The UNC Eshelman School of Pharmacy knows firsthand the value of the work done by the SGC, and we are extremely proud to become a part of it," said Robert Blouin, dean of the school. "We are now at the center of a global network of activity that will generate many opportunities for drug discovery with protein kinases as targets for breakthrough medicines."

The new unit is made up of former employees of GlaxoSmithKline's Research Triangle Park location. GSK, one of the original funders of the SGC, is contributing the rights to use and distribute a library of chemicals developed and characterized by the company.

"The University of North Carolina at Chapel Hill is an outstanding institution, and their involvement in the SGC clearly signals their intent to speed the creation of new medicines for patients," said Aled Edwards, director and CEO of the Structural Genomics Consortium. "We're delighted to welcome UNC as our first site in the U.S."

University of North Carolina at Chapel Hill

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at